Search

Displaying results 5641 - 5650 of 8697 in total
  1. Drug

    Saprisartan

    go.drugbank.com/drugs/DB01347
    Experimental

    The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. … Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure.

    Categories: Angiotensin Receptor Antagonists, Angiotensin II receptor antagonists
  2. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757] … CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene.

  3. Drug

    Clorgiline

    go.drugbank.com/drugs/DB04017
    Experimental

    An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  4. Drug

    Arzoxifene

    go.drugbank.com/drugs/DB06249
    ApprovedWithdrawn

  5. Drug

    Butobarbital

    go.drugbank.com/drugs/DB01353
    ApprovedIllicit

    Butobarbital is a sedative and a hypnotic drug.

  6. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    The risks of medical interaction are weak and GFT14 may be easily combined with statins or other antidiabetic molecules (glitazones). … GFT14 is a new class of medicaction for treatment of cardiometabolic disease.

  7. Drug

    Merbromin

    go.drugbank.com/drugs/DB13392
    Investigational

    It is an organomercuric disodium salt compound and a fluorescein that is available in many countries, except Switzerland, France, Germany, and the United States where the drug was withdrawn from market

  8. Drug

    ATL1101

    go.drugbank.com/drugs/DB05023
    Experimental

    ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis. … ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis.

  9. Drug

    JB991

    go.drugbank.com/drugs/DB05081
    Experimental

    JB991 is a cyclopentenone prostaglandin analogue intended for treatment of psoriasis. … In addition a closely related cyclopentenone prostaglandin analogue has been shown to exert marked anti-inflammatory effect in vivo in an animal model. The drug will be applied topically on the skin.

  10. Target

    P2Y purinoceptor 12

    go.drugbank.com/bio_entities/BE0000110
    TargetHumans

    Receptor for ADP and ATP coupled to G proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation

    Synonyms: ADP-glucose receptor, P2Y12 platelet ADP receptorFunction: G protein-coupled adenosine receptor activity